Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 3
Submit an article Journal homepage
287
Views
74
CrossRef citations to date
0
Altmetric
Drug Evaluation

Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability

Maria Shipkova Zentralinstitut für Klinische Chemie and Laboratoriumsmedizin, Klinikum Stuttgart, Kriegsbergstr. 60, D-70174 Stuttgart, Germany. [email protected]
,
Victor William Armstrong Georg-August-University, Department of Clinical Chemistry, Göttingen, Germany
,
Michael Oellerich Georg-August-University, Department of Clinical Chemistry, Göttingen, Germany
&
Eberhard Wieland Zentralinstitut für Klinische Chemie and Laboratoriumsmedizin, Klinikum Stuttgart, Kriegsbergstr. 60, D-70174 Stuttgart, Germany. [email protected]
Pages 505-526 | Published online: 29 Sep 2005

Bibliography

  • DANOVITCH GM: Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients. Transplant. Proc. (1999) 31(8A):2S–6S.
  • DJAMALI A, PREMASATHIAN N, PIRSCH JD: Outcomes in kidney transplantation. Semin. Nephrol. (2003) 23(3):306–316.
  • SRINIVAS TR, KAPLAN B, MEIER-KRIESCHE HU: Mycophenolate mofetil in solid-organ transplantation. Expert Opin. Pharmacother. (2003) 4(12):2325–2345.
  • OFFERMANN G: Immunosuppression for long-term maintenance of renal allograft function. Drugs (2004) 64(12):1325–1338.
  • DETRY O, DE ROOVER A, DELWAIDE J, MEURISSE M, HONORE P: The use of mycophenolate mofetil in liver transplant recipients. Expert Opin. Pharmacother. (2003) 4(11):1949–1957.
  • CALNE RY: The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet (1960) 20(1):417–418.
  • MURRAY JE, MERRILL JP, DAMMIN GJ, HARRISON JH, HAGER EB, WILSON RE: Current evaluation of human kidney transplantation. Ann. NY Acad. Sci. (1964) 30(120):545–557.
  • CALNE RY: The present status of renal transplantation. Practitioner (1966) 197(181):627–634.
  • MURRAY JE, BARNES BA, ATKINSON J: Fifth report of The Human Kidney Transplant Registry. Transplantation (1967) 5(4):752–774.
  • CALNE RY, WHITE DJ, THIRU S et al.: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1978) 2(8104–5):1323–1327.
  • SHAW LM, NAWROCKI A, KORECKA M, SOLARI S, KANG J: Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther. Drug Monit. (2004) 26(4):347–351.
  • SCHUTZ E, GUMMERT J, MOHR F, OELLERICH M: Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 341(8842):436.
  • ARMSTRONG VW: Principles and practice of monitoring immunosuppressive drugs. J. Lab. Med. (2002) 26(1/2):27–36.
  • TAKEMOTO SK: Patterns and outcomes for maintenance immunosuppression in the UNOS Renal Transplant Registry. Am. J. Transplant. (2002) 2 (Suppl. 3): A42.
  • SOLLINGER HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 60(3):225–232.
  • NO AUTHORS LISTED: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1996) 61(7):1029–1037.
  • NO AUTHORS LISTED: Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet (1995) 345(8961):1321–1325.
  • VANRENTERGHEM Y: The use of mycophenolate mofetil (Cellcept) in renal transplantation. Nephron. (1997) 76(4):392–399.
  • GONWA T, JOHNSON C, AHSAN N et al.: Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation (2003) 75(12):2048–2053.
  • KUYPERS DR, CLAES K, EVENEPOEL P, MAES B, VANRENTERGHEM Y: Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Pharmacol. Ther. (2004) 75(5):434–447.
  • NEU AM, HO PL, FINE RN, FURTH SL, FIVUSH BA: Tacrolimus versus cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr. Transplant. (2003) 7(3):217–222.
  • REMUZZI G, LESTI M, GOTTI E et al. : Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 364(9433):503–512.
  • BURKE GW, CIANCIO G: Show me the money - immunosuppression in kidney transplantation. Lancet (2004) 364(9433):481–483.
  • KIBERD BA, LAWEN J, FRASER AD, KEOUGH-RYAN T, BELITSKY P: Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am. J. Transplant. (2004) 4(7):1079–1083.
  • HONG JC, KAHAN BD: Use of anti- CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation (1999) 68(5):701–704.
  • NASHAN B: Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. Transpl. Int. (2004) 17(6):279–285.
  • MCTAGGART RA, TOMLANOVICH S, BOSTROM A, ROBERTS JP, FENG S: Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation (2004) 78(3):475–480.
  • LO A, EGIDI MF, GABER LW et al. : Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitorfree regimens in cadaveric renal transplantation. Transplantation (2004) 77(8):1228–1235.
  • GOSIO B: Ricerche batteriologiche e chimiche sulle alterazion delmais; contributo alletiologica della pellagra. Ig. Sanita Pubblica Ann. (1896) 7:825.
  • FLOREY HW, GILLIVER K, JENNINGS MA, SANDERS AG: Mycophenolic acid: an antibiotic from Penicillium revicompactum. Lancet (1946) 1:46–49.
  • TRESSLER RJ, GARVIN LJ, SLATE DL: Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int. J. Cancer. (1994) 57(4):568–573.
  • ALLISON AC, EUGUI EM: The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin. Immunopathol. (1993) 14(4):353–380.
  • FRANKLIN TJ, COOK JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem. J. (1969) 113(3):515–524.
  • LEE WA, GU L, MIKSZTAL AR, CHU N, LEUNG K, NELSON PH: Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm. Res. (1990) 7(2):161–166.
  • ALLISON AC, EUGUI EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology (2000) 47(2–3):85–118.
  • RANSOM JT: Mechanism of action of mycophenolate mofetil. Ther. Drug Monit. (1995) 17(6):681–684.
  • COHN RG, MIRKOVICH A, DUNLAP B et al. : Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation (1999) 68(3):411–418.
  • MELE TS, HALLORAN PF: The use of mycophenolate mofetil in transplant recipients. Immunopharmacology (2000) 47(2–3):215–245.
  • JONSSON CA, CARLSTEN H: Mycophenolic acid inhibits inosine 5’- monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int. Immunopharmacol. (2003) 3(1):31–37.
  • NATSUMEDA Y, CARR SF: Human Type I and II IMP dehydrogenases as drug targets. Ann. NY Acad. Sci. (1993) 696:88–93.
  • HUTCHINSON P, JOSE M, ATKINS RC, HOLDSWORTH SR: Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment. Transpl. Immunol. (2004) 13(1):55–61.
  • KLUPP J, VAN GELDER T, DAMBRIN C et al. : Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. J. Heart Lung Transplant. (2004) 23(3):334–351.
  • BRAVO SOTO JA, ESTEBAN DE LA ROSA RJ, LUNA DEL CASTILLO JD et al. : Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients. Transplant. Proc. (2003) 35(4):1355–1359.
  • BARTEN MJ, VAN GELDER T, GUMMERT JF et al. : Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am. J. Transplant. (2002) 2(8):719–732.
  • ALLISON AC, KOWALSKI WJ, MULLER CJ, WATERS RV, EUGUI EM: Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant. Proc. (1993) 25(3 Suppl. 2):67–70.
  • BLAHETA RA, LECKEL K, WITTIG B et al. : Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant. Proc. (1999) 31(1–2):1250–1252.
  • GLOMSDA BA, BLAHETA RA, HAILER NP: Inhibition of monocyte/ endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord. (2003) 41(11):610–609.
  • HEEMANN U, AZUMA H, HAMAR P, SCHMID C, TILNEY N, PHILIPP T: Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transpl. Immunol. (1996) 4(1):64–67.
  • RICHTER M, ZAHN S, RICHTER H, MOHR FW, OLBRICH HG: Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy. J. Heart Lung Transplant. (2004) 23(12):1405–1413.
  • GUMMERT JF, BARTEN MJ, VAN GELDER T, BILLINGHAM ME, MORRIS RE: Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation (2000) 70(7):1038–1049.
  • GREGORY CR, PRATT RE, HUIE P et al. : Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant. Proc. (1993) 25(1 Pt 1):770–771.
  • EUGUI EM, ALMQUIST SJ, MULLER CD, ALLISON AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand. J. Immunol. (1991) 33(2):161–173.
  • TRAPP A, WEIS M: The impact of immunosuppression on endothelial function. J. Cardiovasc. Pharmacol. (2005) 45(1):81–87.
  • SHIMIZU H, TAKAHASHI M, TAKEDA S et al. : Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation (2004) 77(11):1661–1667.
  • DUBUS I, VENDRELY B, CHRISTOPHE I et al. : Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int. (2002) 62(3):857–867.
  • MORRIS RE, WANG J, BLUM JR et al. : Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant. Proc. (1991) 23(2 Suppl. 2):19–25.
  • STEELE DM, HULLETT DA, BECHSTEIN WO et al. : Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant. Proc. (1993) 25(1 Pt 1):754–755.
  • O’HAIR DP, MCMANUS RP, KOMOROWSKI R: Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann. Thorac. Surg. (1994) 58(5):1311–1315.
  • RAISANEN-SOKOLOWSKI A, VUORISTO P, MYLLARNIEMI M, YILMAZ S, KALLIO E, HAYRY P: Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl. Immunol. (1995) 3(4):342–351.
  • SHIMIZU H, TAKAHASHI M, TAKEDA S et al. : Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts. Transpl. Immunol. (2004) 13(3):219–227.
  • DUBUS I, L’AZOU B, GORDIEN M et al. : Cytoskeletal reorganization by mycophenolic acid alters mesangial cell migration and contractility. Hypertension (2003) 42(5):956–961.
  • LUI SL, RAMASSAR V, URMSON J, HALLORAN PF: Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion. Transpl. Immunol. (1998) 6(1):23–32.
  • SHIPKOVA M, WIELAND E, SCHUTZ E et al. : The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant. Proc. (2001) 33(1–2):1080–1081.
  • SCHUTZ E, SHIPKOVA M, ARMSTRONG VW, WIELAND E, OELLERICH M: Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin. Chem. (1999) 45(3):419–422.
  • SHIPKOVA M, ARMSTRONG VW, WEBER L et al. : German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther. Drug Monit. (2002) 24(3):390–399.
  • SHIPKOVA M, BECK H, VOLAND A et al. : Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. Proteomics (2004) 4(9):2728–2738.
  • WIELAND E, SHIPKOVA M, SCHELLHAAS U et al. : Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin. Biochem. (2000) 33(2):107–113.
  • BULLINGHAM R, MONROE S, NICHOLLS A, HALE M: Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol. (1996) 36(4):315–324.
  • BULLINGHAM RE, NICHOLLS AJ, KAMM BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. (1998) 34(6):429–455.
  • PIRSCH JD, SOLLINGER HW: Mycophenolate mofetil - clinical and experimental experience. Ther. Drug Monit. (1996) 18(4):357–361.
  • KUYPERS DR, VANRENTERGHEM Y, SQUIFFLET JP et al. : Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug Monit. (2003) 25(5):609–622.
  • SHUM B, DUFFULL SB, TAYLOR PJ, TETT SE: Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br. J. Clin. Pharmacol. (2003) 56(2):188–197.
  • WEBER LT, SHIPKOVA M, LAMERSDORF T et al. : Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J. Am. Soc. Nephrol. (1998) 9(8):1511–1520.
  • DE NOFRIO D, LOH E, KAO A et al. : Mycophenolic acid concentrations are associated with cardiac allograft rejection. J. Heart Lung Transplant. (2000) 19(11):1071–1076.
  • ENSOM MH, PARTOVI N, DECARIE D, IGNASZEWSKI AP, FRADET GJ, LEVY RD: Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann. Pharmacother. (2003) 37(12):1761–1767.
  • ENSOM MH, PARTOVI N, DECARIE D, DUMONT RJ, FRADET G, LEVY RD: Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther. Drug Monit. (2002) 24(2):310–314.
  • PISUPATI J, JAIN A, BURCKART G et al.: Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J. Clin. Pharmacol. (2005) 45(1):34–41.
  • JAIN A, VENKATARAMANAN R, HAMAD IS et al. : Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J. Clin. Pharmacol. (2001) 41(3):268–276.
  • JENKE A, RENNER U, RICHTE M et al. : Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin. Transplant. (2001) 15(3):176–184.
  • KIEHL MG, SHIPKOVA M, BASARA N et al. : Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin. Biochem. (2000) 33(3):203–208.
  • AW MM, BROWN NW, ITSUKA T et al. : Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl. (2003) 9(4):383–388.
  • DAVID-NETO E, PEREIRA ARAUJO LM, SUMITA NM et al. : Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. Pediatr. Nephrol. (2003) 18(3):266–272.
  • WEBER LT, LAMERSDORF T, SHIPKOVA M et al. : Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther. Drug Monit. (1999) 21(5):498–506.
  • FILLER G: Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl. Int. (2004) 17(3):120–125.
  • ARMSTRONG VW, TENDERICH G, SHIPKOVA M et al. : Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther. Drug Monit. (2005) 27(3):315–321.
  • SHAW LM, KORECKA M, VENKATARAMANAN R, GOLDBERG L, BLOOM R, BRAYMAN KL: Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am. J. Transplant. (2003) 3(5):534–542.
  • WIGGER M, ARMSTRONG VW, SHIPKOVA M et al. : Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. Ther. Drug Monit. (2002) 24(3):438–443.
  • COX VC, ENSOM MH: Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther. Drug Monit. (2003) 25(2):137–157.
  • OELLERICH M, SHIPKOVA M, SCHUTZ E et al. : Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther. Drug Monit. (2000) 22(1):20–26.
  • DIPCHAND AI, PIETRA B, MCCRINDLE BW, ROSEBROOK-BICKNELL HL, BOUCEK MM: Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J. Heart Lung Transplant. (2001) 20(10):1035–1043.
  • JAIN AB, HAMAD I, ZUCKERMAN S et al. : Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl. Surg. (1999) 5(2):101–106.
  • NOWAK I, SHAW LM: Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin. Chem. (1995) 41(7):1011–1017.
  • SHAW LM, MICK R, NOWAK I, KORECKA M, BRAYMAN KL: Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J. Clin. Pharmacol. (1998) 38(3):268–275.
  • SHAW LM, NOWAK I: Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther. Drug Monit. (1995) 17(6):685–689.
  • KAPLAN B, MEIER-KRIESCHE HU, FRIEDMAN G et al. : The effect of renal insufficiency on mycophenolic acid protein binding. J. Clin. Pharmacol. (1999) 39(7):715–720.
  • MUDGE DW, ATCHESON BA, TAYLOR PJ, PILLANS PI, JOHNSON DW: Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther. Drug Monit. (2004) 26(4):453–455.
  • ATCHESON BA, TAYLOR PJ, KIRKPATRICK CM et al. : Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther. Drug Monit. (2004) 26(3):284–286.
  • WEBER LT, SHIPKOVA M, ARMSTRONG VW et al. : The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J. Am. Soc. Nephrol. (2002) 13(3):759–768.
  • SHIPKOVA M, SCHUTZ E, ARMSTRONG VW, NIEDMANN PD, WIELAND E, OELLERICH M: Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant. Proc. (1999) 31(1–2):1135–1137.
  • SHIPKOVA M, ARMSTRONG VW, OELLERICH M, WIELAND E: Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. (2003) 25(1):1–16.
  • SHIPKOVA M, ARMSTRONG VW, WIELAND E et al. : Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br. J. Pharmacol. (1999) 126(5):1075–1082.
  • PICARD N, CRESTEIL T, PREMAUD A, MARQUET P: Characterization of a Phase I metabolite of mycophenolic acid produced by CYP3A4/5. Ther. Drug Monit. (2004) 26(6):600–608.
  • BOWALGAHA K, MINERS JO: The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br. J. Clin. Pharmacol. (2001) 52(5):605–609.
  • SHIPKOVA M, STRASSBURG CP, BRAUN F et al. : Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br. J. Pharmacol. (2001) 132(5):1027–1034.
  • PARKER G, BULLINGHAM R, KAMM B, HALE M: Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J. Clin. Pharmacol. (1996) 36(4):332–344.
  • PICARD N, RATANASAVANH D, PREMAUD A, LE MEUR Y, MARQUET P: Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid Phase II metabolism. Drug Metab. Dispos. (2005) 33(1):139–146.
  • BERNARD O, GUILLEMETTE C: The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab. Dispos. (2004) 32(8):775–778.
  • MACKENZIE PI: Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther. Drug Monit. (2000) 22(1):10–13.
  • BASU NK, KOLE L, KUBOTA S, OWENS IS: Human UDPglucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab. Dispos. (2004) 32(7):768–773.
  • GIRARD H, COURT MH, BERNARD O et al. : Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics (2004) 14(8):501–515.
  • DJEBLI N, PICARD N, LE MEUR Y, SZELAG JC, MARQUET P: Influence of UGT1A9*3 and UGT2B7 (G-840A) polymorphism on MPA metabolism in renal transplant recipients. [Abstract] Ther. Drug Monit. (2005) 27(2):246.
  • BULLINGHAM R, SHAH J, GOLDBLUM R, SCHIFF M: Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br. J. Clin. Pharmacol. (1996) 41(6):513–516.
  • BEHREND M: Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. (2001) 24(9):645–663.
  • NAGANUMA M, SHIGA T, KAWAI A et al. : Influence of food on plasma concentration of mycophenolic acid in a heart transplant patient receiving concomitant tacrolimus. J. Heart Lung Transplant. (2003) 22(9):1065–1066.
  • MORII M, UENO K, OGAWA A et al. : Impairment of mycophenolate mofetil absorption by iron ion. Clin. Pharmacol. Ther. (2000) 68(6):613–616.
  • MUDGE DW, ATCHESON B, TAYLOR PJ et al. : The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation (2004) 77(2):206–209.
  • LORENZ M, WOLZT M, WEIGEL G et al. : Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am. J. Kidney Dis. (2004) 43(6):1098–1103.
  • LIDGATE D, BRANDL M, HOLPER M, ABUBAKARI A, WU X: Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil. Drug Dev. Ind. Pharm. (2002) 28(10):1275–1283.
  • KATO R, OOI K, IKURA-MORI M, TSUCHISHITA Y et al. : Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J. Clin. Pharmacol. (2002) 42(11):1275–1280.
  • PIEPER AK, BUHLE F, BAUER S et al. : The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol. Dial. Transplant. (2004) 19(10):2630–2633.
  • GIMENEZ F, FOEILLET E, BOURDON O et al. : Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin. Pharmacokinet. (2004) 43(10):685–692.
  • WOLFE EJ, MATHUR V, TOMLANOVICH S et al. : Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy (1997) 17(3):591–598.
  • NADERER OJ, DUPUIS RE, HEINZEN EL, WIWATTANAWONGSA K, JOHNSON MW, SMITH PC: The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J. Clin. Pharmacol. (2005) 45(2):219–226.
  • GREGOOR PJ, DE SEVAUX RG, HENE RJ et al. : Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation (1999) 68(10):1603–1606.
  • POU L, BRUNET M, CANTARELL C et al. : Mycophenolic acid plasma concentrations: influence of co-medication. Ther. Drug Monit. (2001) 23(1):35–38.
  • FLECHNER SM, GOLDFARB D, MODLIN C et al. : Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 74(8):1070–1076.
  • SHIPKOVA M, ARMSTRONG VW, KUYPERS D et al. : MMF Creeping Creatinine Study Group. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther. Drug Monit. (2001) 23(6):717–721.
  • VAN GELDER T, KLUPP J, BARTEN MJ, CHRISTIANS U, MORRIS RE: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther. Drug Monit. (2001) 23(2):119–128.
  • KOBAYASHI M, SAITOH H, KOBAYASHI M, TADANO K, TAKAHASHI Y, HIRANO T: Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistanceassociated protein 2 in rats. J. Pharmacol. Exp. Ther. (2004) 309(3):1029–1035.
  • HOLT DW, OSTRAAT O, GRINYO JM et al. : Mycophenolate mofetil may be given at lower doses when used in association with sirolimus in renal transplant patients. [Abstract] Am. J. Transplant. (2001) 1(Suppl. 1):247.
  • SCHUETZ EG, HAZELTON GA, HALL J, WATKINS PB, KLAASSEN CD, GUZELIAN PS: Induction of digitoxigenin monodigitoxoside UDPglucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P450p in primary monolayer cultures of adult rat hepatocytes and in human liver. J. Biol. Chem. (1986) 261(18):8270–8275.
  • CATTANEO D, PERICO N, GASPARI F, GOTTI E, REMUZZI G: Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. (2002) 62(3):1060–1067.
  • VIETRI M, PIETRABISSA A, MOSCA F, PACIFICI GM: Mycophenolic acid glucuronidation and its inhibition by nonsteroidal anti-inflammatory drugs in human liver and kidney. Eur. J. Clin. Pharmacol. (2000) 56(9–10):659–664.
  • SOLDIN SJ, STEELE BW: Mini-review: therapeutic drug monitoring in pediatrics. Clin. Biochem. (2000) 33(5):333–335.
  • AIGRAIN EJ, SHAGHAGHI EK, BAUDOUIN V, POPON M, LOIRAT C: Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients. Transplant. Proc. (2000) 32(2):388–390.
  • FILLER G, FOSTER J, BERARD R, MAI I, LEPAGE N: Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant. Proc. (2004) 36(5):1327–1331.
  • FILLER G, ZIMMERING M, MAI I: Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr. Nephrol. (2000) 14(2):100–104.
  • FILLER G, LEPAGE N, DELISLE B, MAI I: Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther. Drug Monit. (2001) 23(5):514–519.
  • DIRKS NL, HUTH B, YATES CR, MEIBOHM B: Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. (2004) 42(12):701–718.
  • PESCOVITZ MD, GUASCH A, GASTON R et al. : Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am. J. Transplant. (2003) 3(12):1581–1586.
  • SHAW LM, KORECKA M, ARADHYE S et al. : Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J. Clin. Pharmacol. (2000) 40(6):624–633.
  • VAN HEST RM, MATHOT RA, VULTO AG, LE MEUR Y, VAN GELDER T: Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther. Drug Monit. (2004) 26(6):620–625.
  • WANG K, ZHANG H, LI Y et al. : Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant. Proc. (2004) 36(7):2068–2070.
  • SMAK GREGOOR PJ, VAN GELDER T, VAN RIEMSDIJK-VAN OVERBEEKE IC, VOSSEN AC, IJZERMANS JN, WEIMAR W: Unusual presentation of herpes virus infections in renal transplant recipients exposed to high mycophenolic acid plasma concentrations. Transpl. Infect. Dis. (2003) 5(2):79–83.
  • HAYSOM L, ROSENBERG AR, KAINER G et al. : BK viral infection in an Australian pediatric renal transplant population. Pediatr. Transplant. (2004) 8(5):480–484.
  • KUYPERS DR, CLAES K, EVENEPOEL P, MAES B, VANRENTERGHEM Y: Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Pharmacol. Ther. (2004) 75(5):434–447.
  • HUBNER GI, EISMANN R, SZIEGOLEIT W: Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung (2000) 50(10):936–940.
  • MOURAD M, MALAISE J, CHAIB EDDOUR D et al. : Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin. Chem. (2001) 47(1):88–94.
  • GAO SZ, CHAPARRO SV, PERLROTH M et al. : Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J. Heart Lung Transplant. (2003) 22(5):505–514.
  • BIRKELAND SA, HAMILTON-DUTOIT S: Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation (2003) 76(6):984–988.
  • ENGELEN W, VERPOOTEN GA, VAN DER PLANKEN M, HELBERT MF, BOSMANS JL, DE BROE ME: Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin. Nephrol. (2003) 60(2):119–124.
  • ARBEITER K, GREENBAUM L, BALZAR E et al. : Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr. Nephrol. (2000) 14(3):195–197.
  • VAN BESOUW NM, VAN DER MAST BJ, SMAK GREGOOR PJ et al. : Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol. Dial. Transplant. (1999) 14(11):2710–2713.
  • VANRENTERGHEM Y: Anaemia after renal transplantation. Nephrol. Dial. Transplant. (2004) 19 (Suppl. 5): V54–V58.
  • AL-UZRI A, YORGIN PD, KLING PJ: Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis. Pediatr. Transplant. (2003) 7(4):253–264.
  • DALLE IJ, MAES BD, GEBOES KP, LEMAHIEU W, GEBOES K: Crohn’s-like changes in the colon due to mycophenolate? Colorectal Dis. (2005) 7(1):27–34.
  • MAES BD, DALLE I, GEBOES K et al. : Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation (2003) 75(5):665–672.
  • ZMONARSKI SC, BORATYNSKA M, MADZIARSKA K et al. : Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period. Transplant. Proc. (2003) 35(6):2205–2206.
  • PAPADIMITRIOU JC, CANGRO CB, LUSTBERG A et al. : Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int. J. Surg Pathol. (2003) 11(4):295–302.
  • NEERMAN MF, BOOTHE DM: A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid. Pharmacol. Res. (2003) 47(6):523–526.
  • PESCOVITZ MD, CONTI D, DUNN J et al. : Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin. Transplant. (2000) 14(3):179–188.
  • BUDDE K, CURTIS J, KNOLL G et al. : ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. (2004) 4(2):237–243.
  • WIELAND E, SHIPKOVA M, WEBER I et al. : Mycophenolic acyl glucuronide plasma concentrations are higher in kidney transplant recipients suffering from diarrhoea and correlate with interleukin release. [Abstract]. Transplantation (2002) 74:164.
  • SHIPKOVA M, VOLAND A, GRÖNE HJ, ARMSTRONG VW, OELLERICH M, WIELAND E: Relationship between plasma concentrations of mycophenolic acid (MPA) and its acyl glucuronide (AcMPAG) and intestinal damage in wistar rats treated with mycophenolate mofetil (MMF). Ther. Drug. Monit. (2002) 25(4):537(Abstract).
  • SHIPKOVA M, SPIELBAUER B, VOLAND A et al. : cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation (2004) 78(8):1145–1152.
  • DUCLOUX D, OTTIGNON Y, SEMHOUN-DUCLOUX S et al. : Mycophenolate mofetil-induced villous atrophy. Transplantation (1998) 66(8):1115–1116.
  • KAMAR N, FAURE P, DUPUIS E et al. : Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl. Int. (2004) 17(8):463–467.
  • SHRESTHA NK, MOSSAD SB, BRAUN W: Pneumonitis associated with the use of mycophenolate mofetil. Transplantation (2003) 75(10):1762.
  • GALINDO M, CABELLO A, JOVEN B et al. : Mycophenolate mofetil induced myopathy in a patient with lupus nephritis. J. Rheumatol. (2005) 32(1):188–190.
  • NEYLAN JF: Immunosuppressive therapy in high-risk transplant patients: dosedependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1997) 64(9):1277–1282.
  • VAN GELDER T: Mycophenolate mofetil: how to further improve using an already successful drug? Am. J. Transplant. (2005) 5(2):199–200.
  • DAMBRIN C, KLUPP J, MORRIS RE: Pharmacodynamics of immunosuppressive drugs. Curr. Opin. Immunol. (2000) 12(5):557–562.
  • GLANDER P, HAMBACH P, BRAUN KP et al. : Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am. J. Transplant. (2004) 4(12):2045–2051.
  • BARTEN MJ, RAHMEL A, GARBADE J et al. : C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. Transplant. Proc. (2005) 37(2):1360–1361.
  • MEIER-KRIESCHE HU, OJO AO, LEICHTMAN AB et al. : Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J. Am. Soc. Nephrol. (2000) 11(12):2366–2370.
  • ROGERS J, STRATTA RJ, ALLOWAY RR, LO A, HODGE EE: African-American ethnicity is no longer a risk factor for early adverse outcomes in simultaneous kidney-pancreas transplantation with contemporary immunosuppression. Transplant. Proc. (2004) 36(4):1055–1057.
  • LANG P, PARDON A, AUDARD V: Long-term benefit of mycophenolate mofetil in renal transplantation. Transplantation (2005) 79(3 Suppl.):S47-S48.
  • OJO AO, MEIER-KRIESCHE HU, HANSON JA et al. : Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 69(11):2405–2409.
  • MEIER-KRIESCHE HU, STEFFEN BJ, HOCHBERG AM et al. : Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation (2003) 75(8):1341–1346.
  • MEIER-KRIESCHE HU, STEFFEN BJ, HOCHBERG AM et al. : Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am. J. Transplant. (2003) 3(1):68–73.
  • HOSENPUD JD, BENNETT LE: Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation (2001) 72(10):1662–1665.
  • EISEN HJ, KOBASHIGAWA J, KEOGH A et al. : Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. (2005) 24(5):517–525.
  • STRATTA RJ, SHOKOUH-AMIRI MH, EGIDI MF et al. : Long-term experience with simultaneous kidney-pancreas transplantation with portal-enteric drainage and tacrolimus/mycophenolate mofetilbased immunosuppression. Clin. Transplant. (2003) 17 (Suppl. 9):69–77.
  • OSUNKWO I, BESSMERTNY O, HARRISON L et al. : A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol. Blood Marrow Transplant. (2004) 10(4):246–258.
  • KIM JG, SOHN SK, KIM DH et al. : Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur. J. Haematol. (2004) 73(1):56–61.
  • DUDLEY C, POHANKA E, RIAD H et al. : Mycophenolate Mofetil Creeping Creatinine Study Group. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the ’creeping creatinine’ study. Transplantation (2005) 79(4):466–475.
  • KEOGH A: Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation (2005) 79(3 Suppl.):S45–S46.
  • SANCHEZ V, DELGADO JF, MORALES JM et al. : Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant. Proc. (2004) 36(9):2823–2825.
  • ANGERMANN CE, STORK S, COSTARD-JACKLE A et al. : Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients - the IMPROVED multi-centre study. Eur. Heart J. (2004) 25(18):1626–1634.
  • NOBILI V, COMPARCOLA D, SARTORELLI MR, DICIOMMO V, MARCELLINI M: Mycophenolate mofetil in pediatric liver transplant patients with renal dysfunction: preliminary data. Pediatr. Transplant. (2003) 7(6):454–457.
  • BECKEBAUM S, CICINNATI VR, KLEIN CG et al. : Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transplant. Proc. (2004) 36(9):2671–2674.
  • MORENO PLANAS JM, CUERVAS-MONS MARTINEZ V, RUBIO GONZALEZ E et al. : Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am. J. Transplant. (2004) 4(10):1650–1655.
  • VINCENTI F, MONACO A, GRINYO J, KINKHABWALA M, ROZA A: Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am. J. Transplant. (2003) 3(3):306–311.
  • BORROWS R, LOUCAIDOU M, VAN TROMP J et al. : Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am. J. Transplant. (2004) 4(11):1845–1851.
  • FREISE CE, KANG SM, FENG S et al. : Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. Transplant. Proc. (2004) 36(4):1067–1068.
  • HOCKER B, JOHN U, PLANK C et al. : Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation (2004) 78(2):228–234.
  • KHWAJA K, ASOLATI M, HARMON J et al. : Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am. J. Transplant. (2004) 4(6):980–987.
  • HOCKER B, JOHN U, PLANK C et al. : Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation (2004) 78(2):228–234.
  • PASCUAL M, SAIDMAN S, TOLKOFF-RUBIN N et al. : Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation (1998) 66(11):1460–1464.
  • MODER KG: Mycophenolate mofetil: new applications for this immunosuppressant. Ann. Allergy Asthma Immunol. (2003) 90(1):15–19.
  • ASSMANN T, RUZICKA T: New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin. Dermatol. (2002) 20(5):505–514.
  • MOK CC, LAI KN: Mycophenolate mofetil in lupus glomerulonephritis. Am. J. Kidney Dis. (2002) 40(3):447–457.
  • HENEGHAN MA, MCFARLANE IG: Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology (2002) 35(1):7–13.
  • SMAK GREGOOR PJ, VAN GELDER T, WEIMAR W: Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine. Neth. J. Med. (2000) 57(6):233–246.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.